GlassScriptPhysician profile
Andrew G Ross
NPI 1932543998
$10,887.19
in general payments reported to CMS, 2019-2025
29 companies · $2,551 in 2025
The $2,551 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $322 · 2021: $1,127 · 2022: $1,712 · 2023: $2,002 · 2024: $2,410 · 2025: $2,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,930 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,930.24 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,421.94 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,187.31 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Glaxosmithkline, LLC. | $1,181.17 | 2021-2025 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $1,134.92 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $832.30 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $535.18 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.48 | 2022-2025 | Jardiance |
| Ardelyx, INC. | $347.54 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Akebia Therapeutics INC | $320.22 | 2019-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $279.70 | 2023-2025 | |
| Novo Nordisk INC | $258.03 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Calliditas Therapeutics US INC. | $219.04 | 2022-2024 | Tarpeyo |
| Vifor Pharma, INC. | $210.05 | 2020-2024 | Veltassa |
| Novartis Pharmaceuticals Corporation | $200.50 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $195.94 | 2022-2024 | Amvuttra, Onpattro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $195.46 | 2020-2025 | Terlivaz, Acthar |
| Horizon Therapeutics Plc | $171.33 | 2019-2022 | |
| Welch Allyn | $136.23 | 2021 | |
| La Jolla Pharmaceutical Company | $124.59 | 2019 | |
| Alexion Pharmaceuticals, INC. | $104.88 | 2023-2025 | Ultomiris |
| Eisai INC. | $88.34 | 2022 | |
| Genzyme Corporation | $73.78 | 2019-2025 | |
| Fresenius USA Marketing, INC. | $54.28 | 2020-2025 | Velphoro, Velphoro |
| Mozarc Medical US LLC | $29.44 | 2024 | Palindrome |
| Genentech USA, INC. | $26.31 | 2025 | Gazyva |
| Daiichi Sankyo INC. | $25.74 | 2022 | |
| Vyne Pharmaceuticals INC. | $24.35 | 2020 | |
| Xeris Pharmaceuticals, INC. | $22.40 | 2025 | Keveyis |
| Nxstage Medical, INC. | $20.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.